ReviewPostepy dermatologii i alergologii2020
The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines.
Review in Postepy dermatologii i alergologii, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease.Journal of gastroenterology and hepatology · 2026Guideline
- Psoriasis and Psoriatic Arthritis in Pregnancy: Current Evidence and Clinical Considerations.Cureus · 2026Review
- Hidradenitis Suppurativa Treatment During Pregnancy and Lactation: Navigating Challenges.International journal of dermatology · 2025Review
- How Hormonal Balance Changes Lives in Women with Psoriasis.Journal of clinical medicine · 2025Review
- Need for individualized counseling regarding psoriasis systemic therapy in women of childbearing age: analysis of the PsoFem study at the University Medical Center Hamburg.International journal of women's dermatology · 2024Article
- Impact of Psoriasis on Pregnancy Desire and Possible Consequences on Fertility.Dermatology practical & conceptual · 2024Article
- Psoriasis in Childbearing Age: A Real-Life, Retrospective, Single-Center Study on Anti-IL17 and IL-23 Agents.Journal of clinical medicine · 2024Article
- A Review of Hidradenitis Suppurativa in Special Populations: Considerations in Children, Pregnant and Breastfeeding Women, and the Elderly.Dermatology and therapy · 2024Review
- Effect of Anti-TNF Biologic Exposure During Pregnancy on Villitis of Unknown Etiology Diagnoses in Patients with Autoimmune Disease.Reproductive sciences (Thousand Oaks, Calif.) · 2024Article
- Pregnancy Outcomes in Hidradenitis Suppurativa Patients.AMIA ... Annual Symposium proceedings. AMIA Symposium · 2024Article
- Ustekinumab in the Treatment of Generalized Pustular Psoriasis in a Pregnant Patient.Clinical, cosmetic and investigational dermatology · 2024Article
- Inflammatory bowel disease in pregnancy and breastfeeding.Nature reviews. Gastroenterology & hepatology · 2023Review
- Therapy of PsO in Special Subsets of Patients.Biomedicines · 2022Review
- Oversight and Management of Women with Psoriasis in Childbearing Age.Medicina (Kaunas, Lithuania) · 2022Review
- Certolizumab Pegol: A New Therapeutic Approach for Acrodermatitis Continua of Hallopeau.Skin appendage disorders · 2022Article
- Biologics and Small Molecules for Inflammatory Nail Disorders: A Narrative Review.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInformation on the possibility of using biological drugs in psoriasis patients planning to conceive, patients who are pregnant or during lactation is limited.
aimPresenting recommendations published in clinical guidelines regarding the use of biological drugs - adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, secukinumab, tildrakizumab, and ustekinumab, by psoriasis patients in the period of planning pregnancy, during pregnancy or during lactation. MATERIAL AND
methodsThe paper was based on a comprehensive review of over 40 websites of HTA agencies, dermatological associations worldwide and medical databases (PubMed, Embase), the objective of which was to identify clinical guidelines relating to biological treatment of women of childbearing potential, published after 2018, which used GRADE - a system for rating the quality of a body of evidence.
findingsCertolizumab pegol is recommended in women who are planning to conceive. Furthermore, guidelines indicate other TNF-α inhibitors as possible treatment. Certolizumab pegol is also recommended as first-line treatment in pregnant patients. Furthermore, for trimesters 2 and 3, guidelines allow using other TNF-α inhibitors. Treatment with secukinumab and ustekinumab should be discontinued when planning pregnancy or when pregnancy was diagnosed. Biological treatment during pregnancy and lactation (continuation or initiation of treatment) can be used only after an analysis of risks and benefits has been conducted.
conclusionsTNF-α inhibitors seem to be the safest and most researched biological drugs used in psoriasis treatment of patients planning to conceive, during pregnancy or lactation. Given its non-existent or minimal placental permeability, most likely the safest alternative is certolizumab pegol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.